R.PR
REGISTERED-PRINCIPAL REGISTER
15/03/2022
Voltar para busca
Dado oficial do USPTO
FAX PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
04/05/2023
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
28/01/2020
Data de registro
15/03/2022
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/03/2022
Última transação
04/05/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
19/06/2019
Primeiro uso no comércio
19/08/2019
Código do desenho
4
Tipo de titular
03
Localização do titular
Miami, FL, US
Examinador
JACKSON, STEVEN W
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Fax Pharma Inc.
Representantes
Erik Lichter Erik Lichter
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific researchconducting clinical trials for others; Medical laboratory services; Medical research; Medical research services in the field of cancer; Pharmaceutical research and development; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Quality evaluation services for the medical and anesthesia industries; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific investigations for medical purposes; Scientific research; Scientific research and development
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/02/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/02/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
20/01/2022
DPCC
DIVISIONAL PROCESSING COMPLETE
20/01/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/01/2022
IUAF
USE AMENDMENT FILED
22/12/2021
DRRR
DIVISIONAL REQUEST RECEIVED
22/12/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
22/12/2021
EISU
TEAS STATEMENT OF USE RECEIVED
22/12/2021
CHPB
POST PUBLICATION AMENDMENT - ENTERED
02/07/2021
APET
ASSIGNED TO PETITION STAFF
01/07/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/06/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
27/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/04/2021
PUBO
PUBLISHED FOR OPPOSITION
27/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/03/2021
ALIE
ASSIGNED TO LIE
17/03/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/03/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/03/2021
GNFR
FINAL REFUSAL E-MAILED
08/03/2021
CNFR
FINAL REFUSAL WRITTEN
08/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/02/2021
ALIE
ASSIGNED TO LIE
18/02/2021
NREV
NOTICE OF REVIVAL - E-MAILED
25/11/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/11/2020
PETG
PETITION TO REVIVE-GRANTED
25/11/2020
PROA
TEAS PETITION TO REVIVE RECEIVED
25/11/2020
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
16/11/2020
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
16/11/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/04/2020
GNRT
NON-FINAL ACTION E-MAILED
23/04/2020
CNRT
NON-FINAL ACTION WRITTEN
23/04/2020
DOCK
ASSIGNED TO EXAMINER
16/04/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/02/2020
NWAP
NEW APPLICATION ENTERED
31/01/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FAX PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.